# Ginkgo Sleep Quality Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/ginkgo-sleep-quality-randomized-trial-evidence-review
Category: evidence-review
Summary: Ginkgo Sleep Quality Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are s
Last reviewed: 2026-07-30
Reviewed by: Migaku Evidence Review
# Ginkgo Sleep Quality Randomized Trial: What the Evidence Says

## Quick Answer

Ginkgo Sleep Quality Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 narrative review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Effectiveness of Over‐The‐Counter Treatments for Tinnitus Symptom Relief: A Systematic Review | systematic review | 1 | 2026-04-04 | 10.1002/lio2.70398 |
| Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders | narrative review | 3 | 2026-03-12 | 10.3389/fnut.2026.1762061 |

## What The Sources Report

- Addressing subjective tinnitus is challenging as it presents secondary to complex pathophysiology, lacks objective biomarkers, is often associated with comorbid psychological issues, and there are a lack of effective treatment options. [Menon Rahul (2026); evidence level 1]
- Although individual trials report varying degrees of benefit, overall the evidence remains inconsistent and heterogeneous. [Menon Rahul (2026); evidence level 1]
- These limitations have catalyzed an increased global focus on nutraceuticals and phytomedicines possessing multimodal biological activities that transcend mere monoamine reuptake inhibition. [Li Xikun (2026); evidence level 3]
- Unlike prior reviews that focus on individual herbs or broadly defined adaptogens, the present review integrates mechanistic, preclinical, and clinical evidence across these three agents to highlight their complementary rather than redundant actions. [Li Xikun (2026); evidence level 3]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For ginkgo sleep quality randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Menon Rahul (2026). Effectiveness of Over‐The‐Counter Treatments for Tinnitus Symptom Relief: A Systematic Review. DOI: 10.1002/lio2.70398. PMCID: PMC13051942. PMID: 41948711. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open .... https://pmc.ncbi.nlm.nih.gov/articles/PMC13051942/
- Li Xikun (2026). Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders. DOI: 10.3389/fnut.2026.1762061. PMCID: PMC13017319. PMID: 41909050. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13017319/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.